The University of Southampton
University of Southampton Institutional Repository
Warning ePrints Soton is experiencing an issue with some file downloads not being available. We are working hard to fix this. Please bear with us.

Inflammation and dementia: Using rheumatoid arthritis as a model to develop treatments?

Inflammation and dementia: Using rheumatoid arthritis as a model to develop treatments?
Inflammation and dementia: Using rheumatoid arthritis as a model to develop treatments?

Dementia is a major international public health problem which looks set to grow as the ageing population increases. Despite large amounts of investment there has been relatively little progress in developing new therapies to combat this. There is a growing body of evidence that both local and systemic inflammation are important in dementia; with cerebral inflammation occurring secondarily to beta-amyloid plaques, raised levels of serum inflammatory molecules and cytokines being present in Alzheimer's disease patients and systemic inflammation being associated with cerebral microvasculature disease in vascular dementia. Observational studies had suggested that non-steroidal anti-inflammatory drugs may reduce the risk of dementia, but subsequent interventional studies have been disappointing. More recently some observational studies have suggested a protective effect from conventional synthetic disease modifying anti-rheumatic drugs (csDMARDS) and tumour necrosis factor inhibiting (TNFi) biological therapies. Treatments for inflammatory rheumatic diseases have previously been repurposed and used successfully in other diseases, such as TNFi for inflammatory bowel disease. There are also studies looking at the use of csDMARDs such as methotrexate to improve outcomes after cardiovascular events. Ongoing interventional trials are currently looking at whether therapies designed to treat inflammatory and autoimmune diseases have the potential to be used to treat dementia.

Biologic, Dementia, DMARD, Inflammation, Rheumatoid arthritis
1568-9972
919-925
Mason, Alice
3a78776d-13b0-48b5-ba8a-e7ef5b2a057b
Holmes, Clive
ada5abf3-8459-4cf7-be40-3f4e9391cc96
Edwards, Christopher J.
dcb27fec-75ea-4575-a844-3588bcf14106
Mason, Alice
3a78776d-13b0-48b5-ba8a-e7ef5b2a057b
Holmes, Clive
ada5abf3-8459-4cf7-be40-3f4e9391cc96
Edwards, Christopher J.
dcb27fec-75ea-4575-a844-3588bcf14106

Mason, Alice, Holmes, Clive and Edwards, Christopher J. (2018) Inflammation and dementia: Using rheumatoid arthritis as a model to develop treatments? Autoimmunity Reviews, 17 (9), 919-925. (doi:10.1016/j.autrev.2018.04.001).

Record type: Article

Abstract

Dementia is a major international public health problem which looks set to grow as the ageing population increases. Despite large amounts of investment there has been relatively little progress in developing new therapies to combat this. There is a growing body of evidence that both local and systemic inflammation are important in dementia; with cerebral inflammation occurring secondarily to beta-amyloid plaques, raised levels of serum inflammatory molecules and cytokines being present in Alzheimer's disease patients and systemic inflammation being associated with cerebral microvasculature disease in vascular dementia. Observational studies had suggested that non-steroidal anti-inflammatory drugs may reduce the risk of dementia, but subsequent interventional studies have been disappointing. More recently some observational studies have suggested a protective effect from conventional synthetic disease modifying anti-rheumatic drugs (csDMARDS) and tumour necrosis factor inhibiting (TNFi) biological therapies. Treatments for inflammatory rheumatic diseases have previously been repurposed and used successfully in other diseases, such as TNFi for inflammatory bowel disease. There are also studies looking at the use of csDMARDs such as methotrexate to improve outcomes after cardiovascular events. Ongoing interventional trials are currently looking at whether therapies designed to treat inflammatory and autoimmune diseases have the potential to be used to treat dementia.

This record has no associated files available for download.

More information

Accepted/In Press date: 3 April 2018
e-pub ahead of print date: 10 July 2018
Published date: September 2018
Keywords: Biologic, Dementia, DMARD, Inflammation, Rheumatoid arthritis

Identifiers

Local EPrints ID: 425338
URI: http://eprints.soton.ac.uk/id/eprint/425338
ISSN: 1568-9972
PURE UUID: 229e2047-6597-4e90-bf0d-d26746114e4b
ORCID for Clive Holmes: ORCID iD orcid.org/0000-0003-1999-6912

Catalogue record

Date deposited: 12 Oct 2018 16:30
Last modified: 26 Nov 2021 02:42

Export record

Altmetrics

Contributors

Author: Alice Mason
Author: Clive Holmes ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×